文献速递炎症性肠病

HLADQA1*05基因型预测炎症性肠病英夫利西单抗治疗中抗药抗体形成与失应答

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-25

该回顾性队列研究纳入262例接受英夫利西单抗治疗的炎症性肠病患者,评估HLADQA1*05A>G(rs2097432)变异与抗药抗体形成、失应答、停药及不良事件的关系。结果显示变异携带者抗药抗体形成风险显著升高(校正HR=7.29),失应答和停药风险亦增加,但与不良事件无关。

要点

  • HLADQA1*05变异携带者抗药抗体形成风险显著增高(校正HR=7.29)。
  • 变异携带与英夫利西单抗失应答和停药风险增加相关。
  • 变异状态与英夫利西单抗相关不良事件无显著关联。

核心结论

  • HLADQA1*05独立关联英夫利西单抗抗药抗体形成高风险,以及失应答和治疗停药风险增加。
  • 基因型指导的联合免疫抑制治疗在炎症性肠病中可能具有应用价值。

研究设计与样本

  • 回顾性队列研究,纳入262例接受英夫利西单抗治疗的炎症性肠病患者。
  • 检测HLADQA1*05A>G(rs2097432)变异,比较野生型(GG)与变异携带者(AG或AA)的结局。

主要发现

  • 79%的英夫利西单抗抗体阳性患者携带至少一个变异等位基因。
  • 变异携带者抗药抗体形成风险更高(校正HR=7.29,95%CI=2.97-17.191,P=1.46×10^-5),独立于年龄、性别、体重、剂量和联合免疫抑制剂。
  • 变异携带状态与英夫利西单抗失应答风险增加相关(校正HR=2.34,95%CI=1.41-3.88,P=.001)。
  • 变异携带状态与停药风险增加相关(校正HR=2.27,95%CI=1.46-3.43,P=2.53×10^-4),但与英夫利西单抗相关不良事件无显著关联。

临床怎么用

  • 对炎症性肠病患者在启动英夫利西单抗前可考虑检测HLADQA1*05基因型以评估抗药抗体形成风险。
  • HLADQA1*05变异携带者可能需要更密切监测或考虑基因型指导的联合免疫抑制治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-drug antibodies (ADAs) are a leading contributor to infliximab loss of response and adverse drug events. It is not feasible to identify patients at risk of antibody formation before initiating infliximab. The genetic variation HLADQA1*05 (rs2097432) has been linked to infliximab antibody formation in Crohn's disease (CD). AIMS: To evaluate the association between HLADQA1*05 and infliximab antibody formation, infliximab loss of response, treatment discontinuation and adverse drug events in patients with inflammatory bowel disease (IBD) METHODS: In a retrospective cohort study, infliximab-exposed patients with IBD (n = 262) were screened for the genetic variation, HLADQA1*05A>G (rs2097432). Risk of infliximab ADA formation, infliximab loss of response, adverse events and discontinuation were assessed in wild-type (GG) and variant-carrying (AG or AA) individuals. RESULTS: Forty per cent of all participants were HLADQA1*05A>G variant carriers, with 79% of participants with infliximab antibodies carrying at least one variant allele. The risk of infliximab antibody formation was higher in HLADQA1*05A>G variant carriers (adjusted HR = 7.29, 95% confidence interval (CI) = 2.97-17.191, P = 1.46 × 10-5 ) independent of age, sex, weight, dose and co-immunosuppression with an immunomodulator. Variant carrier status was associated with an increased risk of infliximab loss of response (adjusted HR = 2.34, 95% CI = 1.41-3.88, P = .001) and discontinuation (adjusted HR = 2.27, 95% CI = 1.46-3.43, P = 2.53 × 10-4 ) although not with infliximab-associated adverse drug events. CONCLUSIONS: HLADQA1*05 is independently associated with a high risk of infliximab antibody formation in addition to infliximab loss of response and treatment discontinuation. There may be a role for genotype-guided application of combination therapy in IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wilson A, Peel C, Wang Q, et al. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2019. PMID: 31650614. doi:10.1111/apt.15563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。